中国医药(600056.SH)：注射用更昔洛韦通过仿制药一致性评价

Core Viewpoint - China Medical (600056.SH) announced that its wholly-owned subsidiary, Hainan Tongyong Kangli Pharmaceutical Co., Ltd. (referred to as "Kangli Pharmaceutical"), has received two approval notices for the injectable drug Ganciclovir from the National Medical Products Administration (NMPA) [1] Group 1 - The injectable Ganciclovir has passed the consistency evaluation of quality and efficacy for generic drugs [1] - Ganciclovir is primarily used for treating life-threatening or vision-threatening cytomegalovirus infections in immunocompromised patients, as well as for preventing cytomegalovirus infections in organ transplant patients [1]